Zhitong Finance App News, Hutchmed (00013.HK) announced that its subsidiary HUTCHMED (Shanghai) Limited (HUTCHMED) Limited (HUTCHMED) has reached an exclusive development and licensing agreement with a subsidiary of GSK plc (“GlaxoSmithKline”), granting the GlaxoSmithKline subsidiary the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau, and Taiwan. Clinical development will first focus on colorectal cancer, pancreatic cancer, and lung cancer indications. The agreement includes a $110 million down payment and potential development, registration and commercialization milestone payments, totaling $1,295 million, plus royalties based on net sales. This is the world's first (first-in-class) antibody-targeted conjugate drug (ATTC) candidate, using a highly selective, highly active KRAS (Kirsten rat sarcoma) small molecule inhibitor as a payload and conjugated with an anti-epidermal growth factor receptor (EGFR) antibody. ATTC is guided by antibodies, so that the potent cell-killing payload can selectively focus on tumor tissue and exert activity.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.